Lightbridge Corporation — Q1 2023 Form 10-Q
Reporting period: Three months ended March 31, 2023. Lightbridge is a development-stage nuclear fuel technology company focused on developing and commercializing metallic fuel. The unaudited results are not necessarily indicative of full-year results.
Financial results and position
| Metric | Q1 2023 | Q1 2022 / comparator |
|---|---|---|
| Revenue | $0 | $0 |
| Operating expenses | $2.314 million | $2.176 million |
| Operating loss | $2.283 million | $2.053 million |
| Interest income | $256,365 | $3,505 |
| Net loss | $2.027 million; $0.17 per share | $2.050 million; $0.20 per share |
| Cash used in operating activities | $1.580 million | $1.934 million |
- At March 31, cash and cash equivalents were $28.1 million, including $20.0 million in U.S. Treasury bills. Working capital was approximately $27.5 million.
- Total assets were $28.9 million; current liabilities were $576,000. The company reported no debt or lines of credit.
- No gross margin is reported because the company had no revenue. Operating expenses rose about 6%; R&D increased $185,000, while general and administrative expense decreased slightly. Higher interest income largely offset the increase in operating loss.
- Cash declined $849,000 during the quarter. Financing provided $731,000 of net proceeds from ATM share sales; the comparable quarter’s financing proceeds were $5.413 million.
- Shares outstanding increased to 12.126 million from 11.900 million at year-end, reflecting ATM sales and shares issued for services. The filing reports 12,129,688 shares outstanding as of May 11, 2023.
Business developments, outlook, and risks
- Lightbridge reported DOE confirmation of its membership in the HALEU Consortium in January 2023. It is working with Idaho National Laboratory (INL) on development activities, including casting depleted-uranium uranium-zirconium ingots. The company completed a project Quality Implementation Plan during the quarter.
- Management’s planned development steps over the next two to three years include INL work leading toward irradiation testing, a CANDU feasibility study, a pilot-scale fuel-fabrication facility design study, and fuel-alloy extrusion and coupon production. These are forward-looking plans, not completed results.
- Management said existing cash was expected to fund operations for the next 12 months. It projected approximately $13.1 million of expenditures over that period and average long-term outside R&D spending of $10 million annually over 10–15 years. It expects R&D spending and cash burn to rise as work progresses and says substantial future government support will be needed.
- The company had approximately $3.2 million of outstanding INL project task statement obligations. Work may be terminated under the agreements with notice; termination would leave the company responsible for costs incurred and closeout costs, subject to stated task-statement limits.
- The company may use its ATM and other financing sources, but future financing is not assured and equity issuance could dilute existing shareholders. The April 4, 2023 prospectus supplement set the ATM offering capacity at up to $17.9 million, subject to Form S-3 public-float limits.
- Key risks include funding needs, successful fuel testing and commercialization, reliance on government laboratories and strategic partners, development costs and timing, regulatory requirements, competition, and market adoption. Management stated there were no material changes to the risk factors in its 2022 Form 10-K.
- Disclosure controls were deemed ineffective as of March 31, 2023 because of a material weakness involving accounts-payable invoice recording. Remediation steps were underway, but management had not yet determined the weakness remediated. No restatement or change to previously released results was required.
Important facts for investors to verify
- Whether INL work advances on schedule toward irradiation testing, and what milestones, costs, and funding arrangements follow.
- Actual monthly cash burn and R&D commitments against management’s 12-month liquidity estimate, including the effect of increased planned R&D.
- Availability and terms of DOE support, strategic partnerships, and additional financing; monitor ATM usage and resulting dilution.
- Progress in remediating the accounts-payable control weakness and evidence that controls operate effectively.
- Whether fuel testing, licensing, and commercialization assumptions remain achievable given development, regulatory, and market risks.